[
    [
        {
            "time": "2023-10-18",
            "original_text": "AbbVie (ABBV) Stock Moves -0.79%: What You Should Know",
            "features": {
                "keywords": [
                    "AbbVie",
                    "stock moves",
                    "-0.79%"
                ],
                "sentiment_score": -0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "AbbVie (ABBV) Stock Moves -0.79%: What You Should Know",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 8,
                "Market_Scope": 2,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-18",
            "original_text": "AbbVie Announces Executive Leadership Changes",
            "features": {
                "keywords": [
                    "AbbVie",
                    "executive leadership",
                    "changes"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "AbbVie Announces Executive Leadership Changes",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-18",
            "original_text": "Lilly says Taltz superior to Humira in late-stage psoriatic arthritis trial",
            "features": {
                "keywords": [
                    "Lilly",
                    "Taltz",
                    "Humira",
                    "superior",
                    "trial"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Lilly says Taltz superior to Humira in late-stage psoriatic arthritis trial",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]